Vabysmo Syringe and Needle Specifications

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This article responds to your request for information on Vabysmo® (faricimab) and the intravitreal injection syringe and needle specifications.

Please refer to the instructions for use provided in the product label. Any deviation from this information is considered off-label and any treatment decisions based on such deviations are the full responsibility of the prescribing physician.

Download article Download

Last updated September 12, 2023

Materials for Vabysmo intravitreal injection administration

Table 1. Materials for Vabysmo intravitreal injection administration [1,2]

Item of Syringe,Filter needle and Administration needle for Purpose, Description, Material of construction and Included in packaging?

Syringe and administration needle recommendations

Roche/Genentech does not provide recommendations for specific manufacturers or brands of syringe and administration needles to use with Vabysmo. 

Rationale for syringe and administration needle specifications

  • Syringe — Roche/Genentech recommends use of a Luer lock syringe for patient safety.
    • Administration needle — Roche/Genentech recommends a 30-gauge injection needle to avoid increasd injection forces that could be experienced with small diameter needles.

      Material compatibility of Vabysmo

      Polypropylene and polycarbonate

      Roche/Genentech evaluated the physicochemical stability of Vabysmo product in contact with disposable syringes made of polypropylene and polycarbonate. In a simulated intravitreal administration, Vabysmo demonstrated physical and chemical stability for 24 hours at 2°C to 8 °C, when protected from light and stored in polypropylene and polycarbonate syringes.[3]

      Type I borosilicate glass

      As the Vabysmo product comes in a glass vial, compatibility with Type I borosilicate glass is also a given.[3]

      References

      1. Roche Internal Technical Report (Accessed 3 August 2023).
        1. Roche Internal Clinical Study Document (Accessed 3 August 2023).
          1. Roche Internal Communication (Accessed 5 Sept 2022).

            Welcome to Medically

            The Roche Science Hub

            This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

            Not a healthcare professional? Browse:

            This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

            You are Leaving Medically

            By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

            You are Leaving the Global Medically Site

            By following this link, you are being redirected to another Roche page.